<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012696</url>
  </required_header>
  <id_info>
    <org_study_id>210301011</org_study_id>
    <nct_id>NCT05012696</nct_id>
  </id_info>
  <brief_title>Physiological Effects of Non-invasive Mechanical Ventilation Versus High-flow Nasal Cannula in Critically Ill Patients at High Risk of Extubation Failure</brief_title>
  <official_title>Postextubation Non-invasive Ventilation Versus High-flow Nasal Cannula in Critically Ill Patients at High Risk of Weaning Failure: a Physiologic Randomized Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo Nacional de Desarrollo Científico y Tecnológico, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weaning is one of the most complex challenges in mechanically ventilated patients. Increased&#xD;
      work of breathing after extubation would play a central role in weaning failure. Currently,&#xD;
      non-invasive ventilation (NIV) is recommended to prevent weaning failure in high-risk&#xD;
      patients. On the other hand, high-flow nasal cannula (HFNC), which is a novel system capable&#xD;
      of administering gas mixtures (air and oxygen) with a flow of up to 60 liters/min, has been&#xD;
      used to prevent weaning failure in this kind of patients. The use of NIV and HFNC after&#xD;
      extubation has been evaluated in some clinical studies. However, the evidence is&#xD;
      controversial, and the information regarding the physiological effects that each therapy&#xD;
      induces in recently extubated patients at high risk of weaning failure is lacking.&#xD;
&#xD;
      The goal of this proposal is to compare the acute physiological effects of postextubation NIV&#xD;
      versus HFNC in critically ill patients at high risk of weaning failure on relevant mechanisms&#xD;
      related to weaning failure: Work of breathing, lung function, ventilation distribution,&#xD;
      systemic hemodynamics.&#xD;
&#xD;
      This will be a randomized crossover study that will include critically ill mechanically&#xD;
      ventilated patients, who fulfill criteria indicating they may be ready for weaning from&#xD;
      mechanical ventilation, and in whom a spontaneous breathing trial (SBT) is planned to&#xD;
      determine if they should be extubated. After checking eligibility and obtaining informed&#xD;
      consent, patients will be monitored with an esophageal catheter (esophageal/gastric pressures&#xD;
      to determine work of breathing, and electric activity of diaphragm to determine&#xD;
      neuromechanical coupling), and a noninvasive ventilation monitor (electric impedance&#xD;
      tomography to assess global and regional ventilation). Work of breathing, lung function, and&#xD;
      systemic hemodynamics will be assessed during the SBT. Inclusion in the study will be&#xD;
      confirmed only if they pass the SBT and are extubated. During the first 2 hours after&#xD;
      extubation, patients will undergo one hour of NIV and one hour of HFNC, with the crossover&#xD;
      sequence being randomized previously at the time of inclusion and with assessments repeated&#xD;
      at the end of each treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">September 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Analysis of work of breathing and of data derived from Electric impedance tomography will be performed blind to arm assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pressure time-product (PTP) per minute</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Pressure time-product (PTP) per minute (cmH2O x s/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Esophageal pressure swings (ΔPes)</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Esophageal pressure swings (ΔPes) defined as the absolute differences between end-expiratory and end-inspiratory Pes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>End-expiratory lung impedance (EELI)</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>End-expiratory lung impedance (EELI)assessed with Electric impedance tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pressure time-product per breath</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Pressure time-product per breath (cmH2O x s). PTP will be assessed through an esophageal Neurovent catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak electric activity of the diaphragm (EAdi)</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Peak electric activity of the diaphragm (EAdi) EAdi will be measured in uV through a Neurovent catheter connected to a Servo-i ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroventilatory efficiency</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Neuroventilatory efficiency is a parameter derived from the EAdi signal and the ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diaphragmatic neuromuscular coupling</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Diaphragmatic neuromuscular coupling Pdi/EAdi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global inhomogeneity index</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula ]</time_frame>
    <description>Index derived from EIT and calculated from the sum of the impedance changes of each pixel with respect to its median (in absolute values), divided by the sum of the impedance values of each pixel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2 / FiO2 ratio</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Parameter of oxygen exchange calculated as the ratio of PaO2 / FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2</measure>
    <time_frame>60 minutes after starting Non-invasive ventilation or high flow nasal cannula</time_frame>
    <description>Arterial partial pressure of CO2 (PaCO2) Parameter of alveolar ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Weaning From Mechanical Ventilation</condition>
  <arm_group>
    <arm_group_label>Sequence A: Non-invasive ventilation - High flow nasal cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B: High flow nasal cannula - Non-invasive ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive ventilation (NIV)</intervention_name>
    <description>Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.</description>
    <arm_group_label>Sequence A: Non-invasive ventilation - High flow nasal cannula</arm_group_label>
    <arm_group_label>Sequence B: High flow nasal cannula - Non-invasive ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flow nasal cannula</intervention_name>
    <description>High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher &amp; Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.</description>
    <arm_group_label>Sequence A: Non-invasive ventilation - High flow nasal cannula</arm_group_label>
    <arm_group_label>Sequence B: High flow nasal cannula - Non-invasive ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mechanical ventilation (MV) through an orotracheal tube for at least 48 hours&#xD;
&#xD;
          2. PaO2 /FiO2 ratio ≤ 300 mmHg (during the MV period)&#xD;
&#xD;
          3. Potential for weaning&#xD;
&#xD;
               -  Precipitating cause leading to MV in resolution&#xD;
&#xD;
               -  PaO2 /FiO2 ratio ≥ 150 mmHg&#xD;
&#xD;
               -  PEEP ≤ 8 cmH2O&#xD;
&#xD;
               -  pH &gt; 7,25&#xD;
&#xD;
               -  SpO2 ≥ 90% with FiO2 ≤ 0.4; BPM ≤35&#xD;
&#xD;
               -  Hemodynamic stability (noradrenaline ≤ 0.1mcg / kg / min and SBP 90-160; HR &lt;140)&#xD;
&#xD;
               -  Temperature &lt;38 ° C&#xD;
&#xD;
               -  Presence of inspiratory effort and appropriate spontaneous cough&#xD;
&#xD;
               -  Decision to perform a spontaneous breathing trial by the attending physician&#xD;
&#xD;
          4. High risk of weaning failure defined by a history of: (i) Previous failed extubation,&#xD;
             (ii) Chronic heart or respiratory failure, or (iii) MV ≥ 7 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to NIV or HFNC, which include abnormalities, trauma or surgery of&#xD;
             the face or nose.&#xD;
&#xD;
          2. Contraindications for esophageal balloon catheter insertion (eg. severe coagulopathy,&#xD;
             esophageal varices, and history of esophageal or gastric surgery)&#xD;
&#xD;
          3. Contraindication for use of electric impedance tomography (eg. Pacemaker)&#xD;
&#xD;
          4. Tracheostomy&#xD;
&#xD;
          5. Refusal to participate by the attending physician&#xD;
&#xD;
          6. Do not resuscitate order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roque Basoalto, PT, PhD(c)</last_name>
    <phone>5622354564</phone>
    <email>roque.basoalto@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alejandro Bruhn, MD, PhD</last_name>
    <phone>56983260734</phone>
    <email>alejandrobruhn@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico UC Christus</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>114D</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roque Basoalto, PT, PhD(c)</last_name>
      <phone>+56223545649</phone>
      <email>roque.basoalto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alejandro Bruhn, MD, PhD</last_name>
      <phone>+56223543972</phone>
      <email>alejandrobruhn@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roque Basoalto, PT, PhD(c)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Bruhn, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <results_reference>
    <citation>Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P Members Of The Steering Committee, Antonelli M, Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, Mancebo J, Mehta S, Raoof S Members Of The Task Force. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug 31;50(2). pii: 1602426. doi: 10.1183/13993003.02426-2016. Print 2017 Aug. Review.</citation>
    <PMID>28860265</PMID>
  </results_reference>
  <results_reference>
    <citation>Thille AW, Muller G, Gacouin A, Coudroy R, Decavèle M, Sonneville R, Beloncle F, Girault C, Dangers L, Lautrette A, Cabasson S, Rouzé A, Vivier E, Le Meur A, Ricard JD, Razazi K, Barberet G, Lebert C, Ehrmann S, Sabatier C, Bourenne J, Pradel G, Bailly P, Terzi N, Dellamonica J, Lacave G, Danin PÉ, Nanadoumgar H, Gibelin A, Zanre L, Deye N, Demoule A, Maamar A, Nay MA, Robert R, Ragot S, Frat JP; HIGH-WEAN Study Group and the REVA Research Network. Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial. JAMA. 2019 Oct 15;322(15):1465-1475. doi: 10.1001/jama.2019.14901. Erratum in: JAMA. 2020 Feb 25;323(8):793.</citation>
    <PMID>31577036</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1565-1574. doi: 10.1001/jama.2016.14194. Erratum in: JAMA. 2016 Nov 15;316(19):2047-2048. Erratum in: JAMA. 2017 Feb 28;317(8):858.</citation>
    <PMID>27706464</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, Pesenti A. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017 May 1;195(9):1207-1215. doi: 10.1164/rccm.201605-0916OC.</citation>
    <PMID>27997805</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Noninvasive ventilation</keyword>
  <keyword>High-flow nasal cannula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

